Expert Interview
Discussing Sarepta Therapeutics’ gene therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl) and the recently announced results from the Phase 3 EMBARK study.
Ticker(s): SRPTInstitution: Duke University
- Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke.
- Treats hundreds of neuromuscular patients, including 150 Duchenne Muscular Dystrophy patients and 60 Spinal Muscular Atrophy patients
- Actively involved in clinical research and trials with a focus on neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.
Roughly how many patients do you treat per year for DMD?
Added By: sara_adminAre the results from the Phase 3 EMBARK study shocking to you?
Added By: sara_adminDo you believe ELEVIDYS shows clinical promise based on the results from the secondary endpoints in the EMBARK study?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
